June 2025 On June 6, 2025, the European Medicines Agencys (EMA) safety committee concluded that Novo Nordisks semaglutide-containing drugsincluding the popular weight-loss drug Wegovy and diabetes treatments Ozempic and Rybelsusmay cause rare but serious cases of non-arteritic anterior ischemic optic neuropathy (NAION), a sudden and painless vision loss in one eye due to optic nerve damage
Fatty Acid Modification : Leveraging interactions between fatty acids and albumin for metabolic stability and circulation, and using the self-association and ionic properties of fatty acids to extend the drug's half-life
Bruns, C., Lewis, I., Briner, U., Meno-Tetang, G
Management strategies include ensuring adequate protein intake (1.2-1.6 g/kg ideal body weight daily), maintaining proper hydration, considering dose adjustment or delayed escalation, engaging in regular physical activity, and working with a registered dietitian